The efficacy of mafosfamide purging depends on factors like incubation time, drug and erythrocyte concentration. To determine the influence of protein-bound SH groups in the incubation medium, the cytotoxicity of mafosfamide on G-CSF mobilized CD34 + cells was evaluated by short-term culture assays and drug concentration measurements. 100 mol/ml mafosfamide was incubated for 30 min in five buffers (PBS, PBS with 1%, 5% and 10% BSA and plasma). The mean calculated areas under the concentration-time curves (AUC) were 2489 ؎ 198, 1561 ؎ 286, 976 ؎ 201, 585 ؎ 62 and 605 ؎ 196 mol/l/min. The mean reductions of CFU-GM growth were 79.4%, 73.0%, 62.5%, 30.3%, 6.2% respectively. Similar results were obtained for BFU-E. Regression analysis showed a good correlation between cytotoxicity and AUCs (CFU-GM: r = 0.8195; BFU-E: r = 0.8207). This effect is well explained by the different concentrations of SH moieties in the incubation medium resulting in a higher drug binding capacity. The profound difference between AUCs and CFU-GMs in plasma and 10% BSA cannot be explained by the quantity of SH-groups. It is probably due to an additional enzymatic drug degeneration by the 3Ј-5Јexonuclease subsite of plasma DNA polymerase. In conclusion, the concentration of albumin-associated SH groups strongly influences the cytotoxicity of mafosfamide. It has to be considered as a new and important aspect in ex vivo bone marrow purging.
donor could be found. 1, 2 Autologous peripheral blood stem cell transplantation (PBSCT) became available after the introduction of recombinant growth factors such as G-CSF. 3, 4 The collection of hematopoietic progenitor cells by leukapheresis and the rapid engraftment with a shortened period of severe neutropenia are the most pronounced advantages of the PBSCT. While treatment-related mortality is lower for autologous BMT or PBSCT, it lacks the beneficial GVL effect and carries the risk of retransfusing malignant cells. 5, 6 Gene marking studies showed that leukemic blasts could recirculate and contribute to clinical relapse. 7 The latter hazard could be decreased by immunological or pharmacological ex vivo purging strategies. [8] [9] [10] Treatment with mafosfamide (4-sulfo-ethyl-thiocyclophosphamide) has been most often used for acute leukemias since its introduction in 1980. 11 Recently published results from an EBMT study demonstrated a lower relapse rate for AML patients transplanted with mafosfamidepurged bone marrow. 12 The greatest challenge is to minimize the amount of residual malignant cells and thus the clinical risk of relapse while preserving the minimal number of stem cells needed for a successful engraftment. The cytotoxic potential of mafosfamide on various subtypes of hematopoietic progenitors, employing long-term culture initiating cells (LTC-IC) or stroma-adherent CFU-blast assays were investigated by other groups. [13] [14] [15] [16] [17] In addition, several factors were delineated which influence the cytotoxicity of mafosfamide like drug concentration, incubation time and temperature, hematocrit and number of nucleated cells, the accumulating chemotherapy pretreatment, combination with amifostine (WR-2721) and a profound inter-individual difference in drug sensitivity. [18] [19] [20] [21] Giarratana et al 22 added the observation that autologous and allogeneic plasma cause an approximately twofold increase of CFU-GM LD95 and suggested the presence of a specific inhibitor. 22 It is well known that the metabolism of cyclophosphamide is affected by enzymatic drug degradation caused by intra-and extracellular aldehydedehydrogenases. 23, 24 In the present study, we confirm our hypothesis that protein binding of mafosfamide, especially on free SH-moieties of albumin, plays a pivotal role in its purging efficacy.
Materials and methods

Separation of cells
Ten aliquots of leukapheresis products were obtained from eight adult patients with different kinds of hematological malignancies after informed consent. The median age was 54, ranging between 45 and 58 years. All patients were included in different high-dose chemotherapy protocols followed by peripheral blood stem cell transplantation. The mononuclear cells were isolated from the leukapheresis products with a standard density gradient technique using Ficoll-Hypaque (Biochrom, Berlin, Germany), and washed twice in RPMI 1640 (Biochrom) supplemented with 5% acid citrate dextrose solution (Baxter, Munich, Germany), 1% l-glutamine and 1% penicillin-streptomycin. Finally, the mononuclear cells were adjusted to 1 × 10 7 cells/ml in RPMI 1640.
CFC assays
A total of 10 experiments were performed. Following flow cytometric quantification of the CD34-expressing cells, the cell plating concentration was adjusted to 1000 CD34 + cells per dish, which were cultured in a semisolid short-term culture assay in triplicate. Cells were suspended in Iscove's modified Dulbecco's medium (Biochrom) and mixed with 1 ml of 0.9% methylcellulose (HCC4434, Stem Cell Technologies, Vancouver, Canada) supplemented with 30% fetal bovine serum, 1% bovine serum albumin, 1 × 10 Ϫ4 m 2-mercaptoethanol, 2 mm l-glutamine, 3 U/ml EPO, 50 ng/ml rhSCF and 10 ng/mL rhGM-CSF and rhIL3. Cells were dispensed carefully into dishes and distributed by gently tilting to avoid air bubbles or cell enrichment at the rim of each dish. The number of colonies was scored after 14 days of incubation at 37°C and 5% CO 2 on an inverted microscope. Colonies are defined as containing more than 40 cells. Single and multicentric colonies with tightly packed, hemoglobin synthesizing cells were considered together as BFU-E; transparent colonies with more heterogenous and spreading cells were scored as CFU-GM.
Flow cytometric analysis and cell quantification
Flow cytometry was used to quantify precisely each concentration used for drug incubation and cell culture. All flow cytometric analyses were performed on the flow cytometer EPICS XL MCL (Coulter-Immunotech, Krefeld, Germany), equipped with single air-cooled argon ion laser and System II software was used for data acquisition. The flow cytometer was properly aligned and fluorochrome compensation was correctly tuned with respect to signal amplification by means of standardized procedures. Flow cytometric analysis was performed on mononuclear cells, which were adjusted to approximately 1 × 10 6 /ml. All specific monoclonal antibodies, anti-CD45-FITC (HLe1), anti-CD34-PE (HPCA2) and irrelevant isotype-specific antibodies (IgG1-FITC, IgG1-PE) were purchased from Becton Dickinson (Heidelberg, Germany). 100 l specimen and 20 l of each antibody were incubated for 20 min at 4°C in the dark. For the absolute count determination of the mononuclear cells and CD34-expressing cells, 100 l of properly mixed flow count fluorospheres 25, 26 (Coulter-Immunotech), with a known concentration of 1024/l, were added to the prepared specimen. The absolute counts were calculated using the following formula:
where a = total number of cells, b = total number of fluorospheres, c = fluorospheres concentration/l. The pipetting of the specimen and fluorospheres was accurately performed in accordance with the instructions of the manufacturer. The mononuclear cells were discriminated from residual red cells or cell debris by their CD45 immunofluorescence. CD34 + cells were exclusively gated with respect to their fluorescence intensity and low side scatter characteristics. The flow count fluorospheres are polystyrene microparticles containing fluorochromes with a broad emission spectrum of 510-700 nm and are easily detectable using the third fluorescence channel vs forward scatter diagram.
Mafosfamide treatment
A total of 10 experiments were performed. 1 ϫ 10 7 mononuclear cells/ml containing different amounts of CD34 + cells were incubated with 100 mol/ml (50 g/ml) mafosfamide (ASTA medica AG, Frankfurt, Germany). In addition, a negative control without drug incubation was performed. The cells were resuspended in human plasma and different phosphate buffers without protein or supplemented with 1%, 5% and 10% bovine serum albumin. The drug incubation was performed at 37°C for 30 min with frequent agitation. After drug incubation, the cells were kept on ice and washed twice in IMDM. The cytotoxicity of mafosfamide on hematopoietic stem cells was assessed by the reduction of colony numbers in comparison to those of the negative control.
Pharmacological data
The results were obtained by means of six experiments. 100 mol/ml mafosfamide was dissolved in human plasma and the above-mentioned buffers at 37°C. Samples were drawn at 1, 10, 20, 30, 45, 60, 90, 120, 180 and 240 min. The concentration of mafosfamide was measured using a spectrophoto-fluorometer (Aminco-Bowmann, Silver Springs, USA) as described earlier. 27 The areas under the concentration-time curve (AUC) for 30 min were calculated according to the trapezoidal rule using the Topfit program (Version 2.0). The AUC 30 was correlated with the results obtained from the cell culture using Pearson regression analysis.
Statistics
Means and standard deviations were calculated where indicated. To compare the effect of different buffers to both the colony's growth and area under the concentration-time curves, the statistically significant differences were assessed by using a paired t-test. To determine the relationship between both parameters, we performed Pearson regression analysis and calculated the correlation coefficients and 95% confidence intervals. The normal distribution was evaluated by the Kolmogorov-Smirnov test and by using QQ plots.
Results
The clonogenic potential of the CD34 expressing hematopoietic progenitors was evaluated in 10 experiments using a standardized short-term culture assay. The cell culture functions as a surrogate assay to assess the hematopoietic potential of the drug-incubated cells since a more adequate in vitro system for predicting long-term repopulating properties is lacking. The results are given in Figure 1 . The absolute counts of the different lineage committed colonies (CFU-GM, BFU-E) were 126.2 Ϯ 20.7 and 126.6 Ϯ 19.0 respectively, when cells were plated without prior drug incubation. The in vitro mafosfamide treatment using human plasma as the drug incubation medium slightly reduced the CFU-GM and BFU-E growth to 118.3 Ϯ 17.9 and 115.3 Ϯ 17.1 absolute colonies. The corresponding reduction rates were 6.2% and 8.9%, reflecting similar behavior for both kinds of colonies. In contrast, when employing a protein-free phosphate buffer, the absolute number of CFU-GM and BFU-E colonies dropped markedly to 22.9 Ϯ 13.9 and 25.3 Ϯ 11.8. These results represented a 79.4% and 79.9% inhibition of colony growth when compared to those results obtained by the negative control. The addition of 1%, 5% or 10% bovine serum albumin decreased the cytotoxicity of mafosfamide. The absol- Figure 1 The influence of the buffers used for mafosfamide treatment on the growth of colonies. Mononuclear cells containing CD34-expressing cells were plated in triplicate. The colonies were scored after 14 days of incubation on an inverted microscope. Burst-forming units-erythroid (BFU-E) and colony-forming units-granulocyte/monocyte (CFU-GM) were calculated in a methylcellulose-based short-term culture assay. A total of 10 experiments was performed. Mean and s.d. are indicated. The differences between the groups were assessed by using a paired t-test and were considered to be statistically significant at a P Ͻ 0.05 level.
ute CFU-GM and BFU-E colonies were 34. In parallel, we determined the areas under the concentration-time curve using drug concentration measurements. Figure 2 summarizes the pharmacokinetic data of six successive experiments with 100 mol/l mafosfamide. Statistically significant differences are indicated in Figure 2 . The AUC for protein-free phosphate buffer was 2489 Ϯ 198 mol/l/min. The addition of 1% BSA resulted in a decline of the AUC to a mean value of 1561 Ϯ 286 mol/l/min. This pronounced decay of the AUC was further observed using higher albumin concentrations. The corresponding AUC values were 976 Ϯ 201 mol/l/min and 585 Ϯ 62 mol/l/min for both 5% and 10% BSA. Mafosfamide dissolved in human plasma leads to an AUC value of 605 Ϯ 196 mol/l/min, comparable to that of 10% BSA (P = 0.797).
The pharmacokinetic data were correlated with those obtained by the short-term cell culture assay using Pearson correlation. The linear regression analysis showed good correlations (CFU-GM: r = 0.8195 and BFU-E: r = 0.8207) between the area under the concentration-time curves and the reduction of colonies for both CFU-GM and BFU-E (Figure 3a and b) with the exception when plasma-dissolved mafosfamide was employed. There was only a weak inhibition of colony growth (Ͻ10%) observable, whereas in 10% BSA the reduction amounted to more than 30%. This phenomenon could not be confirmed by the pharmacokinetic data showing near-identical AUC values of 585 vs 605 mol/l/min. µ Figure 2 The cytotoxicity of mafosfamide depends on the protein concentration of the buffers used. The areas under the concentration-time curves (AUC) were calculated for 30 min of drug incubation (100 mol/ml mafosfamide) at 37°C. Six experiments were performed. Statistically significant differences are expressed by using a paired t-test. The regression analysis showed a good correlation between the results obtained by drug measurements and those obtained by cell culturing (reduction of CFU-GM (a) and BFU-E (b)). The normal distribution of these data was confirmed by a Kolmogorov-Smirnov test and QQ plots. The regression line (Pearson) and the 95% confidence interval are included.
Discussion
The rationale for mafosfamide purging is based on the different susceptibility of hematopoietic and leukemic cells. 16, 17 To achieve the goal of minimizing contaminating malignant cells while saving the least number of stem cells required for a successful engraftment, pharmacological bone marrow purging with mafosfamide prior to ABMT must be performed according to a reliable experimental procedure. 19 For monitoring the individually tolerable mafosfamide dose without irreversible damage of the pluripotent stem cell pool, the durable engraftment potential was assessed using long-term culture techniques. 13, 14 Several modifying factors are known, such as drug concentration, incubation time, pH and temperature, concentration of red and nucleated cells, enzymatic degradation by aldehydedehydrogenase and a marked inter-individual sensitivity. [18] [19] [20] 24 In addition, Giarratana et al 22 described an important influence of plasma on the cytotoxicity of mafosfamide suggesting that a plasma inhibitor might be responsible for their finding. However, the nature and mechanism of this plasma inhibitor were not elucidated.
Our present data, which are in accordance with Giarratana's findings, imply that an alteration in the mafosfamide pharmacokinetics due to protein binding is the explanation for the decreased cytotoxicity. We demonstrate that the half-lives and subsequently the AUCs of mafosfamide are inversely correlated to the protein content of the incubation media. With regard to our cell culture results, it can be proposed that this pharmacokinetic effect has important implications for the adequate monitoring of mafosfamide purging. Not only the AUC, but also the reduction of colony numbers is strongly influenced by the BSA concentration. The high correlation (r = 0.82) found between AUC and colony reduction emphasizes that this is a good example for a dose (concentration × time) Ϫ response relationship. The type of reaction between mafosfamide and proteins does not seem to be alkylation, because investigations of the metabolism of cyclophosphamide by Voelcker et al 28, 29 showed a reversible but rather stable binding to proteins (especially albumin), which resulted in a marked influence on the drug's half-life. They demonstrated that not the parent drug, but two activated metabolites (4-OH-cyclophosphamide and phosphoramide mustard) react by a thioglycosidation with the SH-moities of proteins, generating a complex without alkylating properties. In contrast, reactions with oligomolecular thiols (like cystein or mesna) resulted in a weaker and immediately reversible binding, which depended on the molar ratio of the reaction partners. Moreover, Voelcker et al found that more than 50% of the protein-bound thiol groups were occupied by the metabolites within 10 min, a velocity which is well in accordance with our findings.
While the pronounced BSA effect is thus well explained, an additional factor must be responsible for the marked difference to the results with human plasma. The total protein content of plasma is lower than the content of 10% BSA, so degradation of cyclophosphamide metabolites by plasma enzymes might play a role. Bielicki et al 30 described that 4-OH-cyclophosphamide could be a substrate for the 3Ј-5Ј exonuclease subsite of DNA polymerase I, which is prevalent in human plasma. Although this reaction (which leads to the generation of phosphoramide mustard), becomes a toxifying step in the proximity of DNA intracellularly, outside the cell it alters the pharmacokinetics and AUC of 4-OH-cyclophosphamide. While phosphoramide mustard is a strong anion and cannot pass the cell membrane (in contrast to 4-OH-cyclophosphamide), this enzymatic step results in a detoxification extracellularly and hence could be the explanation for our findings.
In conclusion, the amount of protein-bound SH groups can substantially alter the pharmacokinetics and subsequently cytotoxicity of mafosfamide. This has to be considered in order to predict correctly the cytotoxicity of mafosfamide in bone marrow purging procedures. Therefore we recommend removal of residual plasma in bone marrow or stem cell products. Mafosfamide purging should be performed following a standardized protocol, in which the drug concentration and incubation time is adapted to the protein concentration of the incubation medium used. AML patients receiving purged autologous stem cells might have a significant survival benefit, so establishing a clearly defined procedure could be of utmost clinical importance.
